Triiodothyronine prevents cardiac ischemia/reperfusion mitochondrial impairment and cell loss by regulating miR30a/p53 axis

Endocrinology (United States)

Volumn 155, Issue 11, 2014, Pages 4581-4590

  Forini, Francesca ^a   Kusmic, Claudia ^a   Nicolini, Giuseppina ^a   Mariani, Laura ^a   Zucchi, Riccardo ^b   Matteucci, Marco ^c   Iervasi, Giorgio ^a,b,c,d   Pitto, Letizia ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c SCUOLA SUPERIORE SANT ANNA   (Italy)

^d FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LIOTHYRONINE; MESSENGER RNA; MICRORNA; MICRORNA 30A; PROTEIN BAX; PROTEIN P53; UNCLASSIFIED DRUG; MIRN30 MICRORNA, RAT; THYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CELL LOSS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; MALE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; NONHUMAN; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SUPPLEMENTATION; ANIMAL; CELL CULTURE; DRUG EFFECTS; GENETICS; HEART MITOCHONDRION; METABOLISM; NEWBORN; PATHOLOGY; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; MALE; MICRORNAS; MITOCHONDRIA, HEART; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; THYROID HORMONES; TRIIODOTHYRONINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908042896     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1106     Document Type: Article

References (48)

1. Dorn GW 2nd. Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc Res. 2009;81:465-473.
2. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol. 2010;72:19-44.
3. Baines CP. The cardiac mitochondrion: nexus of stress. Annu Rev Physiol. 2010;72:61-80.
4. Marín-García J, Goldenthal MJ. Mitochondrial centrality in heart failure. Heart Fail Rev. 2008;13:137-150.
5. Baines CP, Kaiser RA, Purcell NH, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658-662.
6. Nakayama H, Chen X, Baines CP, et al. Ca2+ - and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest. 2007;117:2431-2444.
7. Nakagawa T, Shimizu S, Watanabe T, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005;434:652-658.
8. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007;316:575-579.
9. Barringhaus KG, Zamore PD. MicroRNAs: regulating a change of heart. Circulation. 2009;119:2217-2224.
10. Divakaran V, Mann DL. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res. 2008;103:1072-1083.
11. Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 2007;116:258-267.
12. van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease the sense in antisense. Circ Res. 2008;103:919-928.
13. Aurora AB, Mahmoud AI, Luo X, et al. MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca2+ overload and cell death. J Clin Invest. 2012;122:1222-1232.
14. Wang X, Zhang X, Ren X, et al. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Circulation. 2010;122:1308-1318.
15. Wang JX, Jiao JQ, Li Q, et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med. 2011;17:71-78.
16. Li J, Donath S, Li Y, Qin D, Prabhakar B, Li P. miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet. 2010;6:e1000795.
17. Duisters RF, Tijsen AJ, Schroen B, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res. 2009;104:170-178.
18. Gambacciani C, Kusmic C, Chiavacci E, et al. miR-29a and miR-30c negatively regulate DNMT3a in cardiac ischemic tissues: implications for cardiac remodeling. MICRNACR. 2013;2013:34-44.
19. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell. 2012;149:1536-1548.
20. Villeneuve C, Guilbeau-Frugier C, Sicard P, et al. p53-PGC-1α pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice. Antioxid Redox Signal. 2013;18:5-18.
21. Wrutniak-Cabello C, Casas F, Cabello G. Thyroid hormone action in mitochondria. J Mol Endocrinol. 2001;26:67-77.
22. Goldenthal MJ, Ananthakrishnan R, Marín-García J. Nuclear-mitochondrial cross-talk in cardiomyocyte T3 signaling: a time-course analysis. J Mol Cell Cardiol. 2005;39:319-326.
23. Marín-García J. Thyroid hormone and myocardial mitochondrial biogenesis. Vascul Pharmacol. 2010;52:120-130.
24. Hamilton MA, Stevenson LW, Luu M, Walden JA. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol. 1990;16:91-95.
25. Wiersinga WM, Lie KI, Touber JL. Thyroid hormones in acute myocardial infarction. Clin Endocrinol (Oxf). 1981;14:367-374.
26. Friberg L, Drvota V, Bjelak AH, Eggertsen G, Ahnve S. Association between increased levels of reverse triiodothyronine and mortality after acute myocardial infarction. Am J Med. 2001;111:699-703.
27. Iervasi G, Pingitore A, Landi P, et al. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation. 2003;107:708-713.
28. Pingitore A, Galli E, Barison A, et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008;93:1351-1358.
29. Henderson KK, Danzi S, Paul JT, Leya G, Klein I, Samarel AM. Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. Circ Heart Fail. 2009;2:243-252.
30. Chen YF, Kobayashi S, Chen J, et al. Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats. J Mol Cell Cardiol. 2008;44:180-187.
31. Pantos C, Mourouzis I, Markakis K, Tsagoulis N, Panagiotou M, Cokkinos DV. Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats. Basic Res Cardiol. 2008;103:308-318.
32. Forini F, Lionetti V, Ardehali H, et al. Early long-term L-T3 replacement rescues mitochondria and prevents ischemic cardiac remodelling in rats. J Cell Mol Med. 2011;15:514-524.
33. Weltman NY, Ojamaa K, Savinova OV, et al. Restoration of cardiac tissue thyroid hormone status in experimental hypothyroidism: a dose-response study in female rats. Endocrinology. 2013;154:2542-2552.
34. Nicolini G, Pitto L, Kusmic C, et al. New insights into mechanisms of cardioprotection mediated by thyroid hormones. J Thyroid Res. 2013;2013:264387.
35. Bianco AC, Anderson G, Forrest D, et al. American thyroid association guide to investigating thyroid hormone economy and action in rodent and cell models. Thyroid. 2014;24:88-168.
36. Eyries M, Siegfried G, Ciumas M, et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res. 2008;103:432-4015.
37. Kaptein EM, Beale E, Chan LS. Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review. J Clin Endocrinol Metab. 2009; 94:3663-3675.
38. Pantos C, Mourouzis I, Saranteas T, et al. Thyroid hormone improves postischaemic recovery of function while limiting apoptosis: a new therapeutic approach to support hemodynamics in the setting of ischaemia-reperfusion? Basic Res Cardiol. 2009;104:69-77.
39. Matoba S, Kang JG, Patino WD, et al. p53 regulates mitochondrial respiration. Science. 2006;312:1650-1653.
40. Park JY, Wang PY, Matsumoto T, et al. p53 improves aerobic exercise capacity and augments skeletal muscle mitochondrial DNA content. Circ Res. 2009;105:705-712, 11 p following 712.
41. Hoshino A, Mita Y, Okawa Y, et al. Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart. Nat Commun. 2013;4:2308.
42. Vousden KH. p53: death star. Cell. 2000;103:691-694.
43. Miyashita T, Reed J. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293-299.
44. Whelan RS, Konstantinidis K, Wei AC, et al. Bax regulates primary necrosis through mitochondrial dynamics. Proc Natl Acad Sci USA. 2012;109:6566-6571.
45. Bauersachs J, Thum T. Biogenesis and regulation of cardiovascular microRNAs. Circ Res. 2011;109:334-347.
46. Ye Y, Perez-Polo JR, Qian J, Birnbaum Y. The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol Genomics. 2011;43:534-542.
47. Pantos C, Mourouzis I, Cokkinos DV. Thyroid hormone and cardiac repair/regeneration: from Prometheus myth to reality? Can J Physiol Pharmacol. 2012;90:977-987.
48. Matsumoto S, Sakata Y, Suna S et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ Res. 2013;113:322-326.